Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
13. Januar 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
10. Januar 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
30. Dezember 2021 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through...
Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe Acne
13. Dezember 2021 09:09 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
08. Dezember 2021 09:32 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
06. Dezember 2021 09:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol
02. Dezember 2021 09:15 ET
|
Biofrontera Inc.
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Closing of $15 Million Private Placement
01. Dezember 2021 19:05 ET
|
Biofrontera Inc.
WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
30. November 2021 09:20 ET
|
Biofrontera Inc.
Conference call at 4:30 p.m. Eastern time today WOBURN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
29. November 2021 09:27 ET
|
Biofrontera Inc.
WOBURN, MA., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional...